Literature DB >> 26599050

Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates.

Giuseppe Tosto1,2, Sarah E Monsell3, Stephen E Hawes3,4, Giuseppe Bruno5, Richard Mayeux1,2,6.   

Abstract

BACKGROUND: Extrapyramidal signs (EPS) are frequent in Alzheimer's disease (AD) and core manifestation of related diseases, i.e., dementia with Lewy bodies and Parkinson's disease; furthermore, Lewy bodies and AD-type pathology occur in all three conditions.
OBJECTIVE: To identify clusters of EPS progression over time and their clinical and neuropathological correlates.
METHODS: 3,502 AD patients with longitudinal assessment from the National Alzheimer's Coordinating Center database were included; 394 provided neuropathological data. k-means algorithm was employed to identify clusters of EPS progression and those were compared in terms of cognitive profile, neuropsychiatric features and neuropathological findings.
RESULTS: Three clusters of EPS progression were identified: no/low (n = 1,583), medium (n = 1,259), and high (n = 660) EPS burden. Compared to those with no/low and medium EPS, those with high EPS had greater cognitive and neuropsychiatric impairment, specifically hallucinations. Despite similar AD-pathology across the three clusters, the high EPS cluster had a significantly number of subjects diagnosed with dementia with Lewy bodies.
CONCLUSIONS: Cluster analysis of EPS progression over time identified different subgroups of AD patients with distinct clinical and neuropathological features.

Entities:  

Keywords:  Alzheimer’s disease; K-means clustering; Lewy bodies; extrapyramidal signs; longitudinal studies

Mesh:

Year:  2016        PMID: 26599050      PMCID: PMC4779642          DOI: 10.3233/JAD-150244

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  25 in total

1.  Incidence of and risk factors for hallucinations and delusions in patients with probable AD.

Authors:  J S Paulsen; D P Salmon; L J Thal; R Romero; C Weisstein-Jenkins; D Galasko; C R Hofstetter; R Thomas; I Grant; D V Jeste
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

Review 3.  [Clinical heterogeneity of Alzheimer's disease. Different clinical profiles can predict the progression rate].

Authors:  C A Mangone
Journal:  Rev Neurol       Date:  2004 Apr 1-15       Impact factor: 0.870

4.  KmL: a package to cluster longitudinal data.

Authors:  Christophe Genolini; Bruno Falissard
Journal:  Comput Methods Programs Biomed       Date:  2011-06-25       Impact factor: 5.428

5.  "Untangling" the relationship between Alzheimer disease and dementia with Lewy bodies.

Authors:  Russell H Swerdlow; Kathy L Newell
Journal:  Neurology       Date:  2012-10-03       Impact factor: 9.910

Review 6.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

7.  The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity.

Authors:  L Hansen; D Salmon; D Galasko; E Masliah; R Katzman; R DeTeresa; L Thal; M M Pay; R Hofstetter; M Klauber
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

8.  Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory.

Authors:  D I Kaufer; J L Cummings; P Ketchel; V Smith; A MacMillan; T Shelley; O L Lopez; S T DeKosky
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2000       Impact factor: 2.198

9.  Risk factors for hallucinations in Parkinson's disease: results from a large prospective cohort study.

Authors:  Kangdi Zhu; Jacobus J van Hilten; Hein Putter; Johan Marinus
Journal:  Mov Disord       Date:  2013-03-20       Impact factor: 10.338

10.  Clinical and multimodal biomarker correlates of ADNI neuropathological findings.

Authors:  Jon B Toledo; Nigel J Cairns; Xiao Da; Kewei Chen; Deborah Carter; Adam Fleisher; Erin Householder; Napatkamon Ayutyanont; Auttawut Roontiva; Robert J Bauer; Paul Eisen; Leslie M Shaw; Christos Davatzikos; Michael W Weiner; Eric M Reiman; John C Morris; John Q Trojanowski
Journal:  Acta Neuropathol Commun       Date:  2013-10-09       Impact factor: 7.801

View more
  3 in total

1.  The Application of Unsupervised Clustering Methods to Alzheimer's Disease.

Authors:  Hany Alashwal; Mohamed El Halaby; Jacob J Crouse; Areeg Abdalla; Ahmed A Moustafa
Journal:  Front Comput Neurosci       Date:  2019-05-24       Impact factor: 2.380

2.  Clustering of Countries for COVID-19 Cases based on Disease Prevalence, Health Systems and Environmental Indicators.

Authors:  Syeda Amna Rizvi; Muhammad Umair; Muhammad Aamir Cheema
Journal:  Chaos Solitons Fractals       Date:  2021-07-08       Impact factor: 5.944

3.  Identifying and evaluating clinical subtypes of Alzheimer's disease in care electronic health records using unsupervised machine learning.

Authors:  Nonie Alexander; Daniel C Alexander; Frederik Barkhof; Spiros Denaxas
Journal:  BMC Med Inform Decis Mak       Date:  2021-12-08       Impact factor: 2.796

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.